by | Apr 24, 2025 | Lupus Foundation of America, News & Events
A new study explores the relationship between frailty, the proportion of health deficits present in an individual, as measured by the Systemic Lupus International Collaborating Clinics Frailty Index (SLICC-FI), and future health-related quality of life (HRQoL) in...
by | Apr 22, 2025 | Lupus Foundation of America
Allogene Therapeutics announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to its investigational allogeneic CAR-T therapy, ALLO-329, for three autoimmune conditions: active refractory moderate-to-severe systemic lupus...
by | Apr 21, 2025 | Lupus Foundation of America, News & Events
In a new letter, published in the Journal of the European Academy of Dermatology and Venereology, members of the lupus community underscore the critical need to recognize the unique challenges of cutaneous lupus erythematosus disease (CLE, lupus skin disease). The...
by | Apr 14, 2025 | Lupus Foundation of America
The IMprove Pregnancy in APS with Certolizumab Therapy (IMPACT) clinical trial, supported by the Lupus Foundation of America through a three-year grant, found that certolizumab pegol, a medication that suppresses a protein involved in inflammation, in combination with...
by | Apr 7, 2025 | Lupus Foundation of America
The Lupus Foundation of America (LFA) is excited to share that enrollment for the MiSLE (Mesenchymal Stromal Cells in Systemic Lupus Erythematosus) study was officially completed on February 21, 2025 – a major milestone in the pursuit of new treatment options...
by | Apr 4, 2025 | Lupus Foundation of America
Jill, a lupus warrior dedicated to making a difference, has participated in the Virtual 6 Challenge every year since it began six years ago. Through her journey with lupus, she has found strength, support and a sense of community in the event. Here are her reflections...
